Drug Targeting MCT4 for Melanoma Treatment to Overcome Resistance to BRAF and MEK Inhibitors

Melanoma patients harboring the BRAFV600E mutation frequently display primary or acquired resistance to BRAF/MEK inhibitors. Understanding this chemoresistant phenotype has highlighted the crucial role of metabolic plasticity, which drives a hybrid phenotype utilizing both glycolysis and oxidative phosphorylation. Metabolic proteins, such as the monocarboxylate transporter MCT4 and its chaperone CD147, are significantly upregulated in untreated melanoma samples compared to normal melanocytes, displaying stage-specific dynamics during disease progression across independent patient cohorts. Therefore, they represent promising therapeutic targets to overcome acquired drug resistance. Our study characterized the clinical profiles of CD147 and MCT4 through bioinformatic analysis of patient datasets and functionally validated their targeting in vitro. Subsequently, the effects of the specific MCT4 and CD147 inhibitors, syrosingopine and AC-73 respectively, and the antioxidant polydatin, were evaluated in the human melanoma cell line A375 and its dabrafenib/trametinib resistant subline A375/DT. Our results indicate that AC-73 and polydatin paradoxically may act as pro-survival factors in parental A375 cells, which are characterized by low oxidative stress and reduced CD147 expression. Conversely, in resistant A375/DT cells, which exhibit high oxidative stress and CD147 overexpression, AC-73 or polydatin could be used to eradicate these cells if combined with cytotoxic agents. Notably, syrosingopine, which can be used in combination with dabrafenib in parental A375 cells, demonstrated the highest efficiency in eradicating the resistant A375/DT cells. Finally, our study identifies MCT4 as a potential therapeutic target in advanced melanoma and its inhibitor syrosingopine as a promising adjuvant drug to circumvent resistance to targeted therapy.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2026-11-19
DOI
https://doi.org/10.3390/ijms272210407
Primary Topic
Melanoma and MAPK Pathways
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Drug Targeting MCT4 for Melanoma Treatment to Overcome Resistance to BRAF and MEK Inhibitors

Francesco Facchiano, Catherine Labbaye, Luca Pasquini, Marisa Colone et al.
International Journal of Molecular Sciences
Melanoma and MAPK Pathways
article

Drug Targeting MCT4 for Melanoma Treatment to Overcome Resistance to BRAF and MEK Inhibitors

Francesco Facchiano, Catherine Labbaye, Luca Pasquini, Marisa Colone, Isabella Spinello, Simona Caporali, Ernestina Saulle, Giuseppina Bozzuto, Lauretta Levati
article en

Abstract

Melanoma patients harboring the BRAFV600E mutation frequently display primary or acquired resistance to BRAF/MEK inhibitors. Understanding this chemoresistant phenotype has highlighted the crucial role of metabolic plasticity, which drives a hybrid phenotype utilizing both glycolysis and oxidative phosphorylation. Metabolic proteins, such as the monocarboxylate transporter MCT4 and its chaperone CD147, are significantly upregulated in untreated melanoma samples compared to normal melanocytes, displaying stage-specific dynamics during disease progression across independent patient cohorts. Therefore, they represent promising therapeutic targets to overcome acquired drug resistance. Our study characterized the clinical profiles of CD147 and MCT4 through bioinformatic analysis of patient datasets and functionally validated their targeting in vitro. Subsequently, the effects of the specific MCT4 and CD147 inhibitors, syrosingopine and AC-73 respectively, and the antioxidant polydatin, were evaluated in the human melanoma cell line A375 and its dabrafenib/trametinib resistant subline A375/DT. Our results indicate that AC-73 and polydatin paradoxically may act as pro-survival factors in parental A375 cells, which are characterized by low oxidative stress and reduced CD147 expression. Conversely, in resistant A375/DT cells, which exhibit high oxidative stress and CD147 overexpression, AC-73 or polydatin could be used to eradicate these cells if combined with cytotoxic agents. Notably, syrosingopine, which can be used in combination with dabrafenib in parental A375 cells, demonstrated the highest efficiency in eradicating the resistant A375/DT cells. Finally, our study identifies MCT4 as a potential therapeutic target in advanced melanoma and its inhibitor syrosingopine as a promising adjuvant drug to circumvent resistance to targeted therapy.

International Journal of Molecular SciencesVol. 27(22)
Istituto Superiore di Sanità (IT), Istituto Dermopatico dell'Immacolata (IT), Nini Hospital (LB), Carlo Forlanini Hospital (IT)
Melanoma and MAPK Pathways
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon